The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Alq- care to name the rumoured bidder ?
You forgot Amarin - another JM disaster. As for buying in at 2p and selling out at 18 p, that cannot be viewed as a disaster. As yo well know pharma investing is often about capturing the hype and getting out before reality dawns.
Pomander, I've never relied on Mr Mellon for my mess of potage, but as a self-proclaimed biotech investment guru, he hasn't half made some risible predictions and recommendations (PLE, DBC, which should really be renamed, "WTF", Arrowhead, the gone and forgotten Burnbrae investments. I share your ambivalence regarding SUMM). The jolly wheeze that is Juvenesence also gives off a strong whiff of oversell, but I'm sure that they'll be no shortage of Mellonanists queuing up to support an IPO. JG is an easy target, but he was handed a hard row to hoe, made harder by the expectation created by unfeasible revenue projections. I think it reasonable to suppose that his background has not equipped him to deal with issues which would tax any pharma old hand (scant intellectual property/commercial protection, undefined regulatory paths, an inadequate clinical dossier, manufacturing issues with cost overruns, positioning of an Rx product in what is essentially and OTC market). True, plenty of people around capable of advising on any and all of these issues, but unless you fully grasp how it all fits together, damned difficult to know what you don't know. What is inexcusable is, whether through naivety or cupidity, his history of miscommunication, although I guess total silence is technically not "miscommunication". This has been covered before, but the canister size has made no difference to the NDA submission timeline. The rate-limiting step has always been securing FDA agreement over definition, capture and measurement of subjective endpoints. Everything now rides on successful clinical validation in the (still to be registered) two part Phase III study, although there are several other critical boxes to be ticked. Bunion: for the record (and it's in my posting history), having bought in large at sub-2p (on the back of a very strong acquisition rumour and with a large, unanticipated, bonus burning a hole in my pocket) and sold at around 18p on EMA approval, PLE, my one and only AIM investment, paid handsomely, thank you. My only regret, one almost certainly shared by many, is that I did not dump the lot back in November 2013. The remainder was dribbled out on spikes, last tranche going at around 5p on the back of the RP acquisition rise.
We must remember that Alq admitted a couple of years ago that having bought Plethora and lost money on his investment, he has held a grudge against the company ever since. As regards Regent, I think we all have been disappointed with the managements past performance together with promises of early "money fountains"..........but with a professional pharma company in Recordati now distributing Fortacin across Europe hopefully we should see some long awaited returns for our patience..........I have been considering topping up again at these prices........
Pikey - my point was that it seems somewhat churlish of Alq to ridicule one of the UK's most successful entrepreneurs on a matter unrelated to RP, unless of course he has his own axe to grind with respect JM. Perhaps he was a former consultant to Ple removed by JM ? His deep knowledge of events going back several years would seem to support this. Whilst I understand your frustration with JG I am not sure that all the failings can be laid at his doorstep. The specialist pharma experience lies with Dr Mike and no doubt he will have been assisted by external pharma consultants. The decision to produce a 6 dose can at the request of Recordati was clearly a catastrophic one and why the FDA submission was not simply advanced with the original 20 dose canister has never really been explained. Had it done so, the changes in FDA regulation may well have been avoided but they are now of the control of RP. My disappointment with JG was his failure to explain clearly why the €5m milestone from Recordati had been delayed. He also provided Bignose which much dud information, but was that deliberate or just his best understanding of the situation at the time.? I have always believed that a pharma investment company should be headed up by an experienced pharma specialist, a background in mining makes little sense unless the only objective here is to flog RP.
well pom , I respect your views, plus still believe we have a great product that should do well despite mellons and Gibson ,,, if mellons has had to cut a lot of dead wood , WHY is Gibson still here , no extra licence deals ,, misleads all the time to share holders ,, does not communicate to share holders , in fact does very little but take a huge salary,, perhaps jim believes he is doing a great job ? well I don't , I suggest any one thinking of investing in a mellons company think again , this company is run very , very . badly , and that's being polite, Gibson on face value is a waste of space , I would be happy to say sorry , if proved wrong , just want my money back after five crap years ...